GCIG CA125 response has a high NPV, indicating that patients without a CA125 response after the first cycle of CHK1i therapy are unlikely to see a reduction in tumor burden, which is additionally associated with worse PFS and OS. The gene discussed is MUC16; the disease is neoplasm.